This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Enzo Biochem’s Clinical Laboratory Applies For NY State Health Department Approval For First Assay Based On Its AmpiProbe™ Amplification Platform

Stocks in this article: ENZ

Enzo Biochem Inc. (NYSE:ENZ) announced today the filing of an application with the New York State Department of Health for the first assay based on its proprietary AmpiProbe™ nucleic acid detection platform. Upon approval, the Company plans to market its HCV RNA Quantification Assay for viral load determination through its Enzo Clinical Laboratory. The Company previously announced plans to seek CE-IVD designation for this assay in order to make it available as a diagnostic product in the European Union.

New York State’s Department of Health ensures the quality of clinical laboratory tests, among others, through what is recognized as the country’s most comprehensive licensure program.

The Company said that, compared with other leading platforms currently in use in what it estimates is a $2 billion market for nucleic acid-based tests, assays based on AmpiProbe™ platform may provide substantially greater sensitivity than conventional PCR-based tests. As a result, AmpiProbe™ assays would require less sample input, facilitating paneling or multiple preparations of tests per sample leading to economic efficiencies. The assay’s utilization of this particular Enzo proprietary technology may thus reduce the need of obtaining multiple samples from patients, an important factor for both physicians and the patients.

“Our studies indicate that AmpiProbe™ based assays can provide a superior testing methodology through greater operational efficiency and economy than any similar platform currently on the market,” said Barry Weiner, Enzo President. “By providing cost savings to clinical laboratories as well as potential benefits to medical practices, we believe that our AmpiProbe™ platform can lead to a new generation of nucleic-acid based assays.

“AmpiProbe™ HCV is the first assay developed from Enzo’s proprietary nucleic acid amplification technology, and we view it as potentially a promising example of other molecular-based products that we currently have under development,” Mr. Weiner added.

The Company previously announced that it would present for the first time clinical findings related to AmpiProbe™ at the March 31, 2012 meeting in London, England, of the European Society of Clinical Microbiology and Infectious Diseases. An abstract, entitled “Quantitative Detection of HCV RNA in Human Plasma-serum using the Enzo AmpiProbe™ HCV RNA Assay,” has been accepted for publication in the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) official journal, Clinical Microbiology and Infection (CMI).

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs